Repaglinide-d5

• Description:

  Repaglinide-d5 is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

• Product Name Alternative:

  AG-EE 623ZW D5

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Isotope-Labeled Compounds; Potassium Channel

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Membrane Transporter/Ion Channel; Others

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Purity:

  98.67

• Solubility:

  DMSO : ≥ 50mg/mL

• Smiles:

  O=C(O)C1=CC=C(CC(N[C@H](C2=CC=CC=C2N3CCCCC3)CC(C)C)=O)C=C1OC([2H])([2H])C([2H])([2H])[2H]

• Molecular Formula:

  C27H31D5N2O4

• Molecular Weight:

  457.62

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore) . 2018 Sep;97 (38) :e12476.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1217709-85-7]